30 Sep 2011: Enclosed are the minutes from the Extraordinary General Meeting in NorDiag ASA held today, 30 September 2011.

26,121,065 of a total of 68,603,145 shares and votes were represented at the General Meeting, or approximately 38.1% of the share capital.

All resolutions were made in accordance with the Board of Directors' proposals.
For further information, please contact:

CEO Mårten Wigstøl            Phone. +47 911 65775
CFO Tone Kvåle                  Phone: +47 915 19576
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com

Find the minutes here

Read the notice in Norwegian here